Adjuvant Osimertinib vs Placebo in Completely Resected Stage IA2-IA3 EGFR-mutated NSCLC: The ADAURA2 Phase III StudyJ. Goldman,Y. Tsutani,S. Dacic,Y. Yatabe,M. Majem,X. Huang,A. Chen,T. Van der Gronde,J. HeJOURNAL OF THORACIC ONCOLOGY（2022）引用 0|浏览11暂无评分关键词Osimertinib, Stage IA2/IA3 NSCLC, DFSAI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
